EU Clinical Trial Information System (CTIS)

Brand Logo

Brand Logo Light

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

I searched for some studies on AstraZeneca Clinical Trials, and found these studies that may also be of interest to you.
Here is the link to my search results

Official Title

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Up to approximately 2352 participants will be randomized in a 1:1 ratio. Arm 1 (n=up to approximately 1176) will receive a single dose of tozorakimab.

Up to approximately 2352 participants will be randomized in a 1:1 ratio. Arm 2 (n=up to approximately 1176) will receive matching placebo.

The purpose of this study is to evaluate the effect of tozorakimab as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen on the prevention of death or progression to IMV/ECMO.

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT ID

Patient Level Data

Therapeutic Area

Single IV dose of tozorakimab or matching placebo on Day 1.

Research Site

A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

To evaluate the effect of tozorakimab versus placebo as an add on to Standard of Care (SoC) in participants with viral lung infection requiring supplemental oxygen on the prevention of death or progression to IMV/ECMO.

To evaluate the effect of tozorakimab versus placebo as add-on to Standard of Care (SoC) on all-cause mortality.

To evaluate the effect of tozorakimab versus placebo as add-on to Standard of Care (SoC) on ICU stay.

To evaluate the effect of tozorakimab versus placebo as add-on to Standard of Care (SoC) on the duration of oxygen supplementation.

To evaluate the effect of tozorakimab versus placebo as add-on to Standard of Care (SoC) on prolonging time to death or IMV/ECMO.

To evaluate the effect of Tozorakimab versus Placebo as add-on to Standard of Care (SoC) on prolonging time to death.

To evaluate the effect of Tozorakimab
versus Placebo as add-on to Standard of Care (SoC) on prolonging time to death.

To evaluate the effect of Tozorakimab versus placebo as add-on to Standard of Care (SoC) on ventilator use.

To evaluate the effect of tozorakimab versus placebo as add-on to Standard of Care (SoC) on ICU admissions.

To evaluate the effect of tozorakimab versus placebo as add-on to Standard of Care (SoC) on duration of hospitalisation.

To evaluate the effect of tozorakimab versus placebo as add-on to Standard of Care (SoC) on clinical status as assessed by the Investigator using WHO 10-category ordinal Clinical Progression Scale (0 least severe to 10 most severe).

To evaluate the immunogenicity (presence of tozorakimab anti-drug antibodies in blood serum) in participants with viral lung infection requiring supplemental oxygen.

To evaluate the use of baseline serum IL-33/sST2 complex levels (U/mL) to predict treatment response with tozorakimab versus placebo as add on to Standard of Care (SoC).

Arms	Assigned Interventions
Experimental: Tozorakimab Up to approximately 2352 participants will be randomized in a 1:1 ratio. Arm 1 (n=up to approximately 1176) will receive a single dose of tozorakimab.	Drug: Tozorakimab Single IV dose of tozorakimab or matching placebo on Day 1. Other Name: MEDI3506
Placebo Comparator: Placebo Up to approximately 2352 participants will be randomized in a 1:1 ratio. Arm 2 (n=up to approximately 1176) will receive matching placebo.	Drug: Placebo Single IV dose of tozorakimab or matching placebo on Day 1.

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen - TILIA

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Estimated Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

Trial Results Summaries

Contacts

Contact